Zoetis Inc. (ZTS) Debt to Assets Ratio: 0.61%
The debt to assets ratio for Zoetis Inc. (ZTS) is 0.61% as of Tuesday, June 9, 2026.
ZTS Debt to Assets Ratio Metrics
DEBT TO ASSETS RATIO
0.61%
ZTS Competitors' Debt to Assets Ratio
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| Zoetis Inc. (ZTS) | — | 0.61% |
| Centene Corporation (CNC) | $32.69B | 0.24% |
| IQVIA Holdings Inc. (IQV) | $31.09B | 0.54% |
| Agilent Technologies, Inc. (A) | $38.26B | 0.26% |
| DexCom, Inc. (DXCM) | $30.17B | 0.22% |
| Biogen Inc. (BIIB) | $29.39B | 0.24% |
| Veeva Systems Inc. (VEEV) | $27.37B | 0.01% |
| Humana Inc. (HUM) | $43.60B | 0.27% |
| Waters Corporation (WAT) | $24.19B | 0.29% |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 0.63% |
Leverage Ratios Comparison
Debt/Assets
0.6%
Debt/Equity
2.85
Current Ratio
3.03
Interest Coverage
14.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
- Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
- Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
- Both measure leverage but from different perspectives
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Zoetis Inc. Debt to Assets Ratio Formula & Definition
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. Debt to Assets Ratio FAQ
- What is the debt to assets ratio for Zoetis Inc. (ZTS)?
- The debt to assets ratio for ZTS stock is 0.61%.
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck